

Serial No.: 09/647,019

Filed: September 26, 2000

Page : 2

mimetic thereof or capable of hybridizing to SEQ ID NO:1 under low stringency conditions or a derivative, homolog, analog, chemical equivalent or mimetic of said nucleic acid molecule.

Attorney's Docket No.: 12525-407001 / 2341630/TDO/FMT

6. (Amended) An isolated nucleic acid molecule according to claim 2 wherein said protein has the characteristics of Csl or a functional equivalent thereof.

- 7. (Amended) An isolated nucleic acid molecule according to claim 2 wherein said protein comprises the amino acid sequence substantially as set forth in SEQ ID NO:4.
- 8. (Amended) An isolated nucleic acid molecule according to claim 2 comprising a nucleotide sequence substantially as set forth in SEQ ID NO:3.

11. (Amended) An isolated nucleic acid molecule according to claim 2 wherein said protein comprises the amino acid sequence substantially as set forth in SEQ ID NO:5.

12. (Amended) An isolated nucleic acid molecule according to claim 2 comprising a nucleotide sequence comprising exon regions of which five comprise:

Exon 1 comprising a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in SEQ ID NO:6;

Exon 2 comprising a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in SEQ ID NO:7;

Exon 3 comprising a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in SEQ ID NO:8;

Exon 4 comprising a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in SEQ ID NO:9; and

Exon 5 comprising a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in SEQ ID NO:10,

or capable of hybridizing to a genomic sequence comprising said exon regions under low stringency conditions or a derivative, homolog, analog, chemical equivalent or mimetic of said nucleic acid molecule.





Attorney's Docket No.: 12525-407001 / 2341630/TDO/FMT

Applicant: Richard P. Harvey et a

Serial No.: 09/647,019 Filed

September 26, 2000

Page

- 16. (Amended) An isolated protein comprising an amino acid sequence substantially as set forth in SEQ ID NO:2 or a derivative, homolog or mimetic thereof or having at least about 45% or greater similarity to SEQ ID NO:2 or a derivative, homolog, analog, chemical equivalent or mimetic of said protein.
- 17. (Amended) An isolated protein according to claim 16 encoded by a nucleotide sequence substantially as set forth in SEQ ID NO:1 or a derivative, homolog or mimetic thereof or capable of hybridizing to SEQ ID NO:1 under low stringency conditions or a derivative, homolog, analog, chemical equivalent or mimetic of said protein.



- 19. (Amended) An isolated protein according to claim 16 wherein said protein has the characteristics of Csl or a functional equivalent thereof.
- 20. (Amended) An isolated protein according to claim 16 comprising an amino acid sequence substantially as set forth in SEQ ID NO:4.
- 21. (Amended) An isolated protein according to claim 16 encoded by a nucleotide sequence substantially as set forth in SEO ID NO:3.
- 22. (Amended) An isolated protein according to claim 16 encoded by a nucleotide sequence comprising exon regions of which five comprise:

Exon 1 comprising a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in SEQ ID NO:6;

Exon 2 comprising a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in SEO ID NO:7:

Exon 3 comprising a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in SEQ ID NO:8;

Exon 4 comprising a nucleotide sequence corresponding to the nucleotide sequence substantially as set forth in SEQ ID NO:9; and

Applicant: Richard P. Harvey et a

Serial No.: 09/647,019

Filed : September 26, 2000

Page :

Exon 5 comprising a nucleotide sequence corresponding to the nucleotide sequence

Attorney's Docket No.: 12525-407001 / 2341630/TDO/FMT

substantially as set forth in SEQ ID NO:10,

or capable of hybridizing to a genomic sequence comprising said exon regions under low stringency conditions or a derivative, homolog, analog, chemical equivalent or mimetic of said

protein.

25. (Amended) An isolated protein according to claim 16 comprising an amino acid sequence substantially as set forth in SEQ ID NO:5.

- 26. (Amended) An isolated protein according to claim 16 which protein is a homodimer.
- 27. (Amended) An isolated protein according to claim 16 which protein is a heterodimer.

B3

31. (Amended) A method of modulating muscle cell functional activity in a mammal, said method comprising administering to said mammal an effective amount of a protein according to claim 16 or a derivative, homolog, analog, chemical equivalent or mimetic thereof for a time and under conditions sufficient to modulate the functional activity of said muscle cell.

68

34. (Amended) A method of modulating muscle cell functional activity in a mammal, said method comprising administering to said mammal an effective amount of a nucleic acid molecule according to claim 2 or a derivative, homolog, analog, chemical equivalent or mimetic thereof for a time and under conditions sufficient to modulate the functional activity of said muscle cell.

B9

37. (Amended) A method of modulating cellular functional activity in a mammal, said method comprising administering to said mammal an effective amount of a protein according to claim 16 or a derivative, homolog, analog, chemical equivalent or mimetic thereof

Applicant: Richard P. Harvey et a

Serial No.: 09/647,019

Filed: September 26, 2000

Page : 5

. September 20, 2

for a time and under conditions sufficient to modulate the activity of one or more components of the calcineurin-dependent signaling pathway.

Attorney's Docket No.: 12525-407001 / 2341630/TDO/FMT

PLO

40. (Amended) A method of modulating cellular functional activity in a mammal, said method comprising administering to said mammal an effective amount of a protein according to claim 2 or a derivative, homolog, analog, chemical equivalent or mimetic thereof for a time and under conditions sufficient to modulate the activity of one or more components of the calcineurin-dependent signaling pathway.

BM

- 48. (Amended) A method of treating a mammal, said method comprising administering to said mammal an effective amount of a protein according to claim 16 or a derivative, homolog, analog, chemical equivalent or mimetic thereof for a time and under conditions sufficient to modulate muscle cell functional activity.
- 49. (Amended) A method of treating a mammal, said method comprising administering to said mammal an effective amount of a nucleic acid molecule according to claim 2 or a derivative, homolog, analog, chemical equivalent or mimetic thereof for a time and under conditions sufficient to modulate muscle cell functional activity.

1012

- 59. (Amended) An isolated antibody directed to the protein according to claim 16.
- 60. (Amended) An isolated antibody directed to the nucleic acid molecule according to claim 2.